Foralumab Nasal Spray for ALS

(BANYAN Trial)

This trial tests a nasal spray called foralumab to determine its safety and tolerability in people with amyotrophic lateral sclerosis (ALS), a condition that progressively weakens muscles. Researchers aim to discover if foralumab can reduce brain inflammation, potentially alleviating ALS symptoms. Participants will be compared to those using a placebo (a non-medicinal spray) to assess safety and effectiveness. The trial seeks adults diagnosed with ALS who have experienced muscle weakness or stiffness for 2 years or less. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group.

Research has shown that foralumab nasal spray is generally safe for individuals with conditions like multiple sclerosis (MS). In past studies involving MS patients, the treatment caused no serious side effects, and participants did not exhibit new issues on MRI scans. Some studies even found that foralumab reduced fatigue and improved physical abilities, making daily tasks easier.

Most treatments for ALS, like Riluzole and Edaravone, work by slowing disease progression or reducing oxidative stress. But Foralumab nasal spray offers a fresh approach by harnessing the immune system differently. It's unique because it targets inflammation in the brain and spinal cord through a novel nasal delivery method, potentially offering more direct and effective relief. Researchers are excited about Foralumab because it could modulate the immune response more precisely, possibly leading to better outcomes for ALS patients.

Research has shown that foralumab nasal spray might help with conditions like ALS by reducing inflammation and calming the immune system. In this trial, participants will receive either foralumab or a placebo. Earlier studies with people who have multiple sclerosis, a disease affecting the brain and spinal cord, showed that those using foralumab had stable symptoms and even improvements. Another study found that all patients using foralumab in expanded access programs had stable or improved disability levels after six months. These findings suggest that foralumab could slow the progression of diseases involving nerve damage, like ALS, by reducing inflammation.⁶⁷⁸⁹¹⁰